19.04.2022 - (PLX AI) – AstraZeneca's Enhertu granted Priority Review from the FDA for HER2m NSCLC for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly ...